The new bisphosphonate, Zometa® (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate

Allan Lipton, E. Small, Fred Saad, D. Gleason, David Gordon, M. Smith, Lee Rosen, M. Ortu Kowalski, Dirk Reitsma, John Seaman

Research output: Contribution to journalArticlepeer-review

155 Scopus citations

Fingerprint

Dive into the research topics of 'The new bisphosphonate, Zometa® (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate'. Together they form a unique fingerprint.

Medicine & Life Sciences